Determining the mode of action of bioactive compounds.

Matching bioactive molecules with molecular targets is key to understanding their modes of action (MOA). Moving beyond the mere discovery of drugs, investigators are now just beginning to integrate both biochemical and chemical-genetic approaches for MOA studies. Beginning with simple screens for changes in cell phenotype upon drug treatment, drug bioactivity has been traditionally explored with affinity chromatography, radiolabeling, and cell-based affinity tagging procedures. However, such approaches can present an oversimplified view of MOA, especially in light of the recent realization of the extent of polypharmacology and the unexpected complexity of drug-target interactions. With the advent of more sophisticated tools for genetic manipulation, a flood of powerful techniques has been used to create characteristic drug MOA 'fingerprints'. In particular, whole genome expression profiling and deletion and overexpression libraries have greatly enhanced our understanding of bioactive compounds in vivo. Here we highlight challenges and advances in studying bioactive compound-target interactions.

[1]  Michelle D. Brazas,et al.  Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. , 2005, Drug discovery today.

[2]  Kayoko Yamada,et al.  Screening of cell death genes with a mammalian genome-wide RNAi library. , 2010, Journal of biochemistry.

[3]  R. Fleischmann,et al.  Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. , 1995, Science.

[4]  Anna E Speers,et al.  Chemical Strategies for Activity‐Based Proteomics , 2004, Chembiochem : a European journal of chemical biology.

[5]  Mike Tyers,et al.  Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole , 2011, Molecular systems biology.

[6]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[7]  A. Coulson,et al.  RNA-Mediated Interference as a Tool for Identifying Drug Targets , 2001, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[8]  Ronald W. Davis,et al.  Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.

[9]  Piero Fariselli,et al.  eSLDB: eukaryotic subcellular localization database , 2006, Nucleic Acids Res..

[10]  P. Brown,et al.  Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.

[11]  R. Andersen,et al.  Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. , 2006, Biotechnology journal.

[12]  Shinsuke Ohnuki,et al.  High-Content, Image-Based Screening for Drug Targets in Yeast , 2010, PloS one.

[13]  Elizabeth A. Winzeler,et al.  Genomic profiling of drug sensitivities via induced haploinsufficiency , 1999, Nature Genetics.

[14]  Sean R. Collins,et al.  Exploration of the Function and Organization of the Yeast Early Secretory Pathway through an Epistatic Miniarray Profile , 2005, Cell.

[15]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[16]  C. N. Coleman,et al.  NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells , 2009, Molecular Cancer Therapeutics.

[17]  Minghui Yang,et al.  Chemical Genetic Profiling and Characterization of Small-molecule Compounds That Affect the Biosynthesis of Unsaturated Fatty Acids in Candida albicans* , 2009, The Journal of Biological Chemistry.

[18]  Joshua LaBaer,et al.  Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway , 2006, Nature chemical biology.

[19]  Victoria Chen,et al.  Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity , 2010, Nature Genetics.

[20]  Gary D Bader,et al.  Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants , 2001, Science.

[21]  Robert P. St.Onge,et al.  The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes , 2008, Science.

[22]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[23]  L. Du,et al.  Global fitness profiling of fission yeast deletion strains by barcode sequencing , 2010, Genome Biology.

[24]  Michel Roberge,et al.  Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Chao Zhang,et al.  An integrated platform of genomic assays reveals small-molecule bioactivities. , 2008, Nature chemical biology.

[26]  Charles Boone,et al.  Microarray-based target identification using drug hypersensitive fission yeast expressing ORFeome. , 2011, Molecular bioSystems.

[27]  Sven Bergmann,et al.  A modular approach for integrative analysis of large-scale gene-expression and drug-response data , 2008, Nature Biotechnology.

[28]  S. Ōmura,et al.  STUDIES ON BACTERIAL CELL WALL INHIBITORS , 1979 .

[29]  J. Acker,et al.  Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.

[30]  Corey Nislow,et al.  A survey of yeast genomic assays for drug and target discovery. , 2010, Pharmacology & therapeutics.

[31]  S. Lindquist,et al.  Detection of compounds that rescue Rab1-synuclein toxicity. , 2008, Methods in enzymology.

[32]  R. Olsen,et al.  Identification of Direct Protein Targets of Small Molecules , 2010, ACS chemical biology.

[33]  G. Giaever,et al.  Yeast Barcoders: a chemogenomic application of a universal donor-strain collection carrying bar-code identifiers , 2008, Nature Methods.

[34]  P. Hergenrother,et al.  Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. , 2011, ACS chemical biology.

[35]  B. Cravatt,et al.  Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. , 2008, Annual review of biochemistry.

[36]  Canguo Zhao,et al.  Expression-Based In Silico Screening of Candidate Therapeutic Compounds for Lung Adenocarcinoma , 2011, PloS one.

[37]  Corey Nislow,et al.  A unique and universal molecular barcode array , 2006, Nature Methods.

[38]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[39]  S. Lory,et al.  Identification of Small Molecule Inhibitors of Pseudomonas aeruginosa Exoenzyme S Using a Yeast Phenotypic Screen , 2008, PLoS genetics.

[40]  B. Cravatt,et al.  Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[42]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[43]  Edward W. Tate,et al.  Activity-based probes: discovering new biology and new drug targets. , 2011, Chemical Society reviews.

[44]  Terry Roemer,et al.  Genome-Wide Fitness Test and Mechanism-of-Action Studies of Inhibitory Compounds in Candida albicans , 2007, PLoS pathogens.

[45]  Yang Li,et al.  PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. , 2008, Chemistry & biology.

[46]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[47]  Ulrich Schlecht,et al.  Gene Annotation and Drug Target Discovery in Candida albicans with a Tagged Transposon Mutant Collection , 2010, PLoS pathogens.

[48]  P. Youngman,et al.  Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. , 2007, Chemistry & biology.

[49]  Taro L. Saito,et al.  High-dimensional and large-scale phenotyping of yeast mutants. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Kishony,et al.  Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.

[51]  Mike Tyers,et al.  Off-Target Effects of Psychoactive Drugs Revealed by Genome-Wide Assays in Yeast , 2008, PLoS genetics.

[52]  B. Cravatt,et al.  Activity-based Proteomics of Enzyme Superfamilies: Serine Hydrolases as a Case Study* , 2010, The Journal of Biological Chemistry.

[53]  J. Davies,et al.  The world of subinhibitory antibiotic concentrations. , 2006, Current opinion in microbiology.

[54]  Elo Leung,et al.  Targeted Genome Editing Across Species Using ZFNs and TALENs , 2011, Science.

[55]  J. McClure,et al.  Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  E. Brown,et al.  Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. , 2004, Chemistry & biology.

[57]  H. Kitano,et al.  In Vivo Robustness Analysis of Cell Division Cycle Genes in Saccharomyces cerevisiae , 2006, PLoS genetics.

[58]  T. Hughes,et al.  Mapping pathways and phenotypes by systematic gene overexpression. , 2006, Molecular cell.

[59]  Lani F. Wu,et al.  Image-based multivariate profiling of drug responses from single cells , 2007, Nature Methods.

[60]  R. Solé,et al.  Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.

[61]  Benjamin F. Cravatt,et al.  Activity-based protein profiling for biochemical pathway discovery in cancer , 2010, Nature Reviews Cancer.

[62]  Yudong D. He,et al.  Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.

[63]  A. Klug,et al.  Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases , 2008, Proceedings of the National Academy of Sciences.

[64]  B. Spratt Properties of the penicillin-binding proteins of Escherichia coli K12,. , 1977, European journal of biochemistry.

[65]  G. Giaever,et al.  Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis , 2009, BMC Microbiology.

[66]  Jyoti Pande,et al.  Phage display: concept, innovations, applications and future. , 2010, Biotechnology advances.

[67]  A. Feig,et al.  Peptide inhibitors targeting Clostridium difficile toxins A and B. , 2010, ACS chemical biology.

[68]  T. Roemer,et al.  Isolation, structure elucidation, and biological activity of virgineone from Lachnum Wirgineum using the genome-wide Candida albicans fitness test. , 2009, Journal of natural products.

[69]  D. Drubin,et al.  A yeast killer toxin screen provides insights into a/b toxin entry, trafficking, and killing mechanisms. , 2009, Developmental cell.

[70]  Mike Tyers,et al.  Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. , 2011, Nature chemical biology.

[71]  Jeff Piotrowski,et al.  Combining functional genomics and chemical biology to identify targets of bioactive compounds. , 2011, Current opinion in chemical biology.

[72]  Corey Nislow,et al.  Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures , 2007, Nature Protocols.

[73]  Sandra Tenreiro,et al.  Transcriptomic Profiling of the Saccharomyces cerevisiae Response to Quinine Reveals a Glucose Limitation Response Attributable to Drug-Induced Inhibition of Glucose Uptake , 2009, Antimicrobial Agents and Chemotherapy.

[74]  Ronald W. Davis,et al.  Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar–coding strategy , 1996, Nature Genetics.

[75]  Liangjiang Wang,et al.  Microarray data integration for genome-wide analysis of human tissue-selective gene expression , 2010, BMC Genomics.

[76]  Grant W. Brown,et al.  Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways , 2004, Nature Biotechnology.

[77]  Douglas A Lauffenburger,et al.  A mammalian functional-genetic approach to characterizing cancer therapeutics. , 2010, Nature chemical biology.

[78]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[79]  G. Thallinger,et al.  YPL.db2: the yeast protein localization database, version 2.0 , 2005, Yeast.

[80]  G. Bammert,et al.  Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[81]  Christoph Freiberg,et al.  The impact of transcriptome and proteome analyses on antibiotic drug discovery. , 2004, Current opinion in microbiology.

[82]  K. Shaw,et al.  Transcriptional profiling and drug discovery. , 2003, Current opinion in pharmacology.

[83]  Eric D Brown,et al.  Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity. , 2010, Chemistry & biology.

[84]  Roy Kishony,et al.  Networks from drug–drug surfaces , 2007, Molecular systems biology.

[85]  Michael I. Jordan,et al.  Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Yixue Li,et al.  Gene expression module-based chemical function similarity search , 2008, Nucleic acids research.

[87]  Corey Nislow,et al.  Combination chemical genetics. , 2008, Nature chemical biology.

[88]  Anna Y. Lee,et al.  Reverse Genetics in Candida albicans Predicts ARF Cycling Is Essential for Drug Resistance and Virulence , 2010, PLoS pathogens.

[89]  E. Brown,et al.  Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. , 2009, Nature chemical biology.

[90]  Yolanda T. Chong,et al.  A picture is worth a thousand words: Genomics to phenomics in the yeast Saccharomyces cerevisiae , 2009, FEBS letters.

[91]  Peter G Schultz,et al.  A genome-wide overexpression screen in yeast for small-molecule target identification. , 2005, Chemistry & biology.

[92]  R. W. Davis,et al.  Targeted selection of recombinant clones through gene dosage effects. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Ian Dunham,et al.  A systematic library for comprehensive overexpression screens in Saccharomyces cerevisiae , 2008, Nature Methods.

[94]  Inmar E. Givoni,et al.  Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.

[95]  Corey Nislow,et al.  Recent advances and method development for drug target identification. , 2010, Trends in pharmacological sciences.

[96]  Gary D Bader,et al.  The Genetic Landscape of a Cell , 2010, Science.

[97]  Corey Nislow,et al.  Yeast chemical genomics and drug discovery: an update. , 2008, Trends in pharmacological sciences.

[98]  Shin-ichi Sato,et al.  Biochemical target isolation for novices: affinity-based strategies. , 2010, Chemistry & biology.

[99]  S. Chandrasegaran,et al.  Custom-designed zinc finger nucleases: What is next? , 2007, Cellular and Molecular Life Sciences.

[100]  G. Church,et al.  A global view of pleiotropy and phenotypically derived gene function in yeast , 2005, Molecular systems biology.

[101]  R. Dasgupta,et al.  An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway , 2011, Proceedings of the National Academy of Sciences.

[102]  Robert P. St.Onge,et al.  Genome-Wide Requirements for Resistance to Functionally Distinct DNA-Damaging Agents , 2005, PLoS genetics.

[103]  D. Hughes,et al.  A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor. , 2010, Nature chemical biology.

[104]  Stuart L Schreiber,et al.  A small molecule suppressor of FK506 that targets the mitochondria and modulates ionic balance in Saccharomyces cerevisiae. , 2003, Chemistry & biology.

[105]  Michael Riffle,et al.  The Yeast Resource Center Public Image Repository: A large database of fluorescence microscopy images , 2010, BMC Bioinformatics.

[106]  K. Shokat,et al.  Chemical Genetics: Where Genetics and Pharmacology Meet , 2007, Cell.

[107]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[108]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[109]  Timothy J Mitchison,et al.  Small molecule screening by imaging. , 2006, Current opinion in chemical biology.

[110]  Y. Ohya,et al.  Diversity of Ca2+-Induced Morphology Revealed by Morphological Phenotyping of Ca2+-Sensitive Mutants of Saccharomyces cerevisiae , 2007, Eukaryotic Cell.

[111]  Meredith C Henderson,et al.  Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer , 2009, Journal of Translational Medicine.

[112]  Filip Pattyn,et al.  Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds , 2009, Clinical Cancer Research.